Vimentin, an abundant cytoplasmic intermediate filament protein, is recognized for its important role in stabilizing intracellular structure. Vimentin has been recognized for its mechanical role in cell plasticity and stress absorbers. Additionally, the functions of vimentin, similar to all other cytoplasmic intermediate filaments, are correlated to its ability to interact with cellular components responsible for signaling as well as kinases, therefore exerting control on gene regulatory networks. Moreover, several studies reveal a novel form of vimentin present at the surface of the plasma membrane or released in the extracellular environment in different physiological and pathological conditions. Based on data pertaining to vimentin's location outside of the cell, novel functions have emerged. The vimentin promoter is complex and appears to be controlled by a combination of positive and negative regulatory elements. In this review, we first present the involvement of these regulatory elements as well as epigenetic regulation of vimentin in different physiological and pathological contexts, including cell growth, cell differentiation, cancer, epithelial to mesenchymal transition and viral infection. Furthermore, this review also analyzes the secretion of vimentin, its presence at the cell surface, the role of extracellular vimentin as a specific marker, its function as a receptor for the von Willebrand factor as well as the entry of viruses, requirements for pathogen invasion, transcellular migration, and the immune response. Finally, a discussion is featured regarding the delocalization of vimentin that may contribute to diseases and disorders.
Peripheral nerve trauma and regeneration are complex events, and little is known concerning how occurrences in the distal stump affect the cell body's response to injury. Intermediate filament (IF) proteins underpin cellular architecture and take part in nerve cell proliferation, differentiation and axon regeneration, but their role in these processes is not yet fully understood. The present study aimed to investigate the regulation and interrelationship of major neural IFs in adult dorsal root ganglion (DRG) neurons and satellite glial cells (SGCs) following sciatic nerve injury. We demonstrated that the expression of neural IFs in DRG neurons and SGCs after axotomy depends on vimentin activity. In intact DRGs, synemin M and peripherin proteins are detected in small neurons while neurofilament L (NFL) and synemin L characterize large neurons. Both neuronal populations are surrounded by vimentin positive- and glial fibrillary acidic protein (GFAP)-negative SGCs. In response to axotomy, synemin M and peripherin were upregulated in large wild-type DRG neurons and, to a lesser extent, in vim-/- and synm-/DRG neurons, suggesting the role for these IFs in axon regeneration. However, an increase in the number of NFLpositive small neurons was observed in vim-/- mice, accompanied by a decrease of peripherin-positive small neurons. These findings suggest that vimentin is required for injury-induced neuronal IF remodeling. We further show that vimentin is also indispensable for nerve injury-induced GFAP upregulation in perineuronal SGCs and that inactivation of vimentin and synemin appears to accelerate the rate of DRG neurite regeneration at early stages in vitro.
We and others propose vimentin as a possible cellular target for the treatment of COVID-19. This innovative idea is so recent that it requires further attention and debate. The significant role played by vimentin in virus-induced infection however is well established: (1) vimentin has been reported as a co-receptor and/or attachment site for SARS-CoV; (2) vimentin is involved in viral replication in cells; (3) vimentin plays a fundamental role in both the viral infection and the consequent explosive immune-inflammatory response and (4) a lower vimentin expression is associated with the inhibition of epithelial to mesenchymal transition and fibrosis. Moreover, the absence of vimentin in mice makes them resistant to lung injury. Since vimentin has a twofold role in the disease, not only being involved in the viral infection but also in the associated life-threatening lung inflammation, the use of vimentin-targeted drugs may offer a synergistic advantage as compared with other treatments not targeting vimentin. Consequently, we speculate here that drugs which decrease the expression of vimentin can be used for the treatment of patients with COVID-19 and advise that several Food and Drug Administration-approved drugs be immediately tested in clinical trials against SARS-CoV-2, thus broadening therapeutic options for this type of viral infection.
This review analyzes data concerning patients with cardiomyopathies or skeletal myopathies associated with a variation in the intermediate filament (IF) synemin gene ( SYNM), also referred to as desmuslin ( DMN). Molecular studies demonstrate that synemin copolymerizes with desmin and vimentin IF and interacts with vinculin, α-actinin, α-dystrobrevin, dystrophin, talin, and zyxin. It has been found that synemin is an A-kinase-anchoring protein (AKAP) that anchors protein kinase A (PKA) and modulates the PKA-dependent phosphorylation of several cytoskeletal substrates such as desmin. Because several IF proteins, including desmin, have been implicated in human genetic disorders such as dominant or recessive congenital and adult-onset myopathy, synemin becomes a significant candidate for cardiac and skeletal myopathies of unknown etiology. Because SYNM is a new candidate gene that displays numerous sequence polymorphisms, in this review, we summarize the genetic and clinical literature about SYNM mutations. Protein-changing variants (missense, frameshifts, nonsense) were further evaluated based on structural modifications and amino acid interactions. We present in silico modeling of helical salt-bridges between residues to evaluate the impact of the synemin networks crucial to interactions with cytoskeletal proteins. Finally, a discussion is featured regarding certain variants that may contribute to the disease state.
Previous studies have shown that proteasome inhibition can have beneficial effects in dystrophic mouse models. In this study, we have investigated the effects of a new selective proteasome inhibitor, CLi, a strong caspase-like inhibitor of the 20S proteasome, on skeletal and cardiac muscle functions of mdx mice. In the first series of experiments, five-month-old male mdx mice (n = 34) were treated with 2 different doses (20 and 100 μg/kg) of CLi and in the second series of experiments, five-month-old female mdx (n = 19) and wild-type (n = 24) mice were treated with 20 μg/kg CLi and Velcade (1 mg/kg) for 1-month. All animals were treadmill exercised twice a week to worsen the dystrophic features. In the first series of experiments, our results demonstrated that 20 μg/kg CLi did not significantly increase absolute and specific maximal forces in skeletal muscle from male mdx mice. Moreover, the higher susceptibility to contraction induced skeletal muscle injury was worsened by 100 μg/kg CLi since the force drop following lengthening contractions was increased with this high dose. Furthermore, we found no differences in the mRNA levels of the molecular markers implicated in dystrophic features. Concerning cardiac function, CLi had no effect on left ventricular function since ejection and shortening fractions were unchanged in male mdx mice. Similarly, CLi did not modify the expression of genes implicated in cardiac remodeling. In the second series of experiments, our results demonstrated an improvement in absolute and specific maximal forces by CLi, whereas Velcade only increased specific maximal force in female mdx mice. In addition, exercise tolerance was not improved by CLi. Taken together, our results show that CLi treatment can only improve maximal force production in exercised female mdx mice without affecting either exercice tolerance capacity or cardiac function. In conclusion, selective inhibition of caspase-like activity of proteasome with CLi has no compelling beneficial effect in dystrophic mdx mice.
Characteristics of the intermediate filament proteins (IFPs) expressed during the development and cell differentiation of peripheral neurons are here reviewed. Neurofilament triplet proteins (NFPs), peripherin, α-internexin, synemin, syncoilin, nestin, vimentin and glial fibrillary acidic protein (GFAP) are each produced by different genes. NFPs, the most extensively studied, are thought to maintain axonal caliber, thus ensuring normal axonal transport, but this network is highly disrupted in several diseases, particularly motor neuron diseases. α-internexin has been proposed as the fourth NFP subunit. The relative plasticity of the peripherin network may account for its possible role during development, when axons have to find their targets, and when axons regenerate. In addition to their expression in muscle, other IFPs, such as syncoilin and synemin, are also expressed in neuronal tissues. Syncoilin modulates peripherin filament networks. Synemin M, associated with peripherin, is present in small unmyelinated fibers, whereas synemin L is produced in large neurons with myelinated fibers positive for the light-chain neurofilament (NF-L) subunit. Nestin is an IFP expressed in dividing cells during early stages of development in the central and peripheral nervous systems, and in muscles and other tissues. After differentiation, nestin is downregulated and replaced by tissue-specific IFPs. IFPs in glial cells are primarily composed of GFAP, although vimentin is also expressed; vimentin is also widely distributed in mesenchymal derivatives and established cell lines. In the peripheral nervous system, NFPs appear early in its development and progressively replace vimentin, which is expressed before NFPs in most, if not all, dividing neuroepithelial cells. In addition, in tissues undergoing an injury response, the unique and complex cell and tissue distribution of IFPs can be markedly modified.
Desmin, the muscle-specific intermediate filament, is involved in myofibrillar myopathies, dilated cardiomyopathy and muscle wasting. Desmin is the target of posttranslational modifications (PTMs) such as phosphorylation, ADP-ribosylation and ubiquitylation as well as nonenzymatic modifications such as glycation, oxidation and nitration. Several PTM target residues and their corresponding modifying enzymes have been discovered in human and nonhuman desmin. The major effect of phosphorylation and ADP-ribosylation is the disassembly of desmin filaments, while ubiquitylation of desmin leads to its degradation. The regulation of the desmin filament network by phosphorylation and ADP-ribosylation was found to be implicated in several major biological processes such as myogenesis, myoblast fusion, muscle contraction, muscle atrophy, cell division and possibly desmin interactions with its binding partners. Phosphorylation of desmin is also implicated in many forms of desmin-related myopathies (desminopathies). In this review, we summarize the findings on desmin PTMs and their implication in biological processes and pathologies, and discuss the current knowledge on the regulation of the desmin network by PTMs. We conclude that the desmin filament network can be seen as an intricate scaffold for muscle cell structure and biological processes and that its dynamics can be affected by PTMs. There are now precise tools to investigate PTMs and visualize cellular structures that have been underexploited in the study of desminopathies. Future studies should focus on these aspects.
Synemin, a type IV intermediate filament (IF) protein, forms a bridge between IFs and cellular membrane. An A-kinase anchoring protein, it also provides temporal and spatial targeting of protein kinase A (PKA). However, little is known about its functional roles in either process. To better understand its functions in muscle tissue, we generated synemin-deficient (Synm−/−) mice. Synm−/− mice displayed normal development and fertility but had mild degeneration/regeneration of myofibres and defects in sarcolemma membranes. Following mechanical overload, Synm−/− mice muscles showed a higher hypertrophic capacity with increased maximal force and fatigue resistance than control mice. At the molecular level, increased remodelling capacity was accompanied by decreased myostatin and atrogin expression and increased follistatin expression. Further, the activity of muscle mass control molecules (PKA-RIIa, p70S6K, CREB) was increased in mutant mice. Finally, analysis of muscle satellite cell behavior suggested that the absence of synemin could affect the balance between self-renewal and differentiation of these cells. Taken together, our results show that synemin is necessary to maintain membrane integrity and regulates signalling molecules during muscle hypertrophy.
The purpose of this study was to establish an MRI protocol on a clinical scanner for assessment of left (LV) and right (RV) ventricular myocardial function of the murine heart, and to apply this protocol for the first in vivo assessment of myocardial function in a mouse model of cardiomyopathy (Desmin−/−). MRI was performed on a clinical 3 T whole body MRI system using a dedicated solenoid receive-only coil. Contiguous short axis slices were acquired covering the entire heart using a spoiled cine gradient echo sequence (TR 9–12 ms, TE 3–4 ms, α 25°, 1.0 × 0.23 × 0.23 mm³). Global LV- and RV-myocardial functional parameters such as end-diastolic ventricular volume, ejection fraction (EF), LV mass and cardiac output (CO) of Desmin−/− mice and age-matched controls were determined. Global myocardial functional data of healthy controls (n = 4) were in very good agreement with previously reported data. The transgenic mice (n = 8) revealed a significantly reduced LV- and RV-EF as well as CO. Body weight-normalized LV- and RV-end-diastolic volumes and LV mass were significantly increased. In addition desmin deficient mice exhibited segmental wall thinning and akinesia, suggesting myocardial necrosis. This study demonstrates that clinical 3 T MRI-systems may reliably be used for non-invasive assessment of LV- and RV-myocardial function in normal and in genetically engineered mice with cardiomyopathies. In addition, this proof of principle study presents first in vivo MRI data of the cardiac phenotype of desmin knock-out mice.
Insets show close-ups of representative fibers (boxed). Arrows in panels a and b indicate mitochondria-rich fibers. (B and C) Immunofluorescence microscopy of soleus and EDL cross sections immunostained for desmin and mitochondria (B) and soleus longitudinal sections labeled for plectin and mitochondria (C). Note the colocalization of plectin and mitochondria along Z-disks in f-ple fibers (C, a, arrow) and the thick, longitudinal mitochondrial aggregates in cKO-ple and des fibers (C, b and c). (D) Electron microscopy showing cytoplasmic aggregates of mitochondria (a and b), scarce association of mitochondria with Z-disks, and Z-disk misalignments (a and c); panels b and c are magnifications of the boxed areas in panel a. (E) Quantitative immunoblotting of f-ple and cKO-ple gastrocnemius and EDL lysates. Data shown in left panel are from gastrocnemius; the bar graph (right) represents pooled data from gastrocnemius and EDL relative to f-ple muscle (100%). α-actinin was used as a loading control. Data were collected from at least five mice per genotype. Values represent means ± SEM. (F) Biochemical analysis of mitochondrial respiratory activities. Citrate synthase, complex I (NADH–Q1), and complex IV (COX) were measured in f-ple and cKO-ple soleus from 8-wk-old mice ( = 12). Mean values (U/g wet weight) ± SEM are shown. *, P Copyright information: Taken from Myofiber integrity depends on desmin network targeting to Z-disks and costameres via distinct plectin isoformsThe Journal of Cell Biology 2008;181(4):667-681.Published online 19 May 2008PMCID:PMC2386106.
Background Intermediate filaments (IFs) are major components of the mammalian cytoskeleton and expressed in cell-type-specific patterns. Morphological changes during cell differentiation are linked to IF network remodeling. However, little is known concerning the presence and the role of IFs in embryonic stem (ES) cells and during their differentiation. Results We have examined the expression profile of synemin isoforms in mouse pluripotent ES cells and during their neural differentiation induced by retinoic acid. Using RT-PCR, Western blotting and immunostaining, we show that synemin M is present at both mRNA and protein levels in undifferentiated ES cells as early as pluripotency factor Oct-3/4 and IF keratin 8. Synemin H was produced only in neural precursors when neural differentiation started, concurrently with synemin M, nestin and glial fibrillary acidic protein. However, both synemin H and M were restricted to the progenitor line during the neural differentiation program. Our in vivo analysis also confirmed the expression of synemins H/M in multipotent neural stem cells in the subventricular zone of the adult brain, a neurogenic germinal niche of the mice. Knocking down synemin in ES cells by shRNA lentiviral particles transduction has no influence on expression of Oct4, Nanog and SOX2, but decreased keratin 8 expression. Conclusions Our study shows a developmental stage specific regulation of synemin isoforms in ES cells and its neural derivatives. These findings represent the first evidence that synemins could potentially be useful markers for distinguishing multipotent ES cells from undifferentiated neural stem cells and more committed progenitor cells.
Intracellular protein filaments intermediate in size between actin filaments and microtubules are composed of a variety of tissue specific proteins. The sequence conservation of the coiled-coil alpha-helical structure responsible for polymerization into individual 10 nm filaments defines a large gene family. Intermediate filaments (IFs) include the nuclear lamins, which are universal in Metazoans, and the cytoplasmic intermediate filaments, which are more varied and form cell type specific networks in animal cells. IFs all share a common tripartite structure consisting of a highly conserved central helical rod domain and variable N-head and C-tail domains. In contrast to actin and tubulin, IFs do not require nucleoside triphosphates such as ATP or GTP for polymerization but they self assemble. According to sequences, the IFs proteins are grouped into seven classes, including five cytoplasmic, one nuclear and one sub-cortical localizations. The search for functions of IFs has led to discoveries of roles in the skin, heart, muscle, liver and brain, in premature aging and of involvement in several degenerative disorders. Mutations in IFs cause or predispose to more than 80 human tissue-specific diseases. Mouse models and gene invalidation have been extremely helpful in eliciting IF role in physiopathology. Besides mechanical role in cell plasticity and stress absorbers, IF functions are related to the capacity to interact with signaling molecules and cell kinases, controlling gene regulatory networks. The reviews herein include a historical perspective about IFs, describe how mutations affect IF structure and assembly properties in desminopathies, inclusion formation in the neurodegenerative Alexander disease, and how they induce multiple disorders in laminopathies.
Disorganization of the desmin network is associated with cardiac and skeletal myopathies characterized by accumulation of desmin-containing aggregates in the cells. Multiple associations of intermediate filament proteins form a network to increase mechanical and functional stability. Synemin is a desmin-associated type VI intermediate filament protein. Neither its impact on desmin network nor how it integrates into desmin filament is yet elucidated. To gain more insight into the molecular basis of these processes, we coexpressed synemin with different desmin mutants in ex vivo models. The screening of fourteen desmin mutants showed that synemin with desmin mutants revealed two behaviors. Firstly, synemin was co-localized in desmin aggregates and its coexpression decreased the number of cells containing aggregates. Secondly, synemin was excluded from the aggregates, then synemin had no effect on desmin network organization. Among fourteen desmin mutants, there were only three mutants, p.E401K, p.R406W and p.E413K, in which synemin was not found in aggregates. This behavior was correlated to the abnormal salt-bridges of desmin-dimer as seen in silico constructs. Moreover, desmin constructs in silico and published results in literature have predicted that the salt-bridges absence in the desmin filament building prevent longitudinal annealing and/or radial compaction. These results suggest that the state of desmin-filament assembly is crucial for synemin anchorage and consequently might involve mechanical and functional stability of the cytoskeletal network.
The intermediate filament (IF) synemin gene encodes three IF proteins (H 180, M 150, L 41 kDa) with overlapping distributions. Synemin M was present early with vimentin and nestin. Synemin H was found later in the nervous system and mesodermic derivatives concomitantly with angiogenesis and the migration of neural crest cells. Synemin L appeared later in neurons. A series of in vitro cell cultures were done to identify the linkage between synemin isoforms and specific cell types of the central nervous system (CNS). The neurons and glia from the brains of humans and rats were cultured and double immunostaining done with antibodies against the H/M or L synemin isoforms and neural cell types (betaIII-tubulin or NeuN) or astrocyte intermediate filaments (GFAP or vimentin). In neurons of the CNS, synemin H/M were co-expressed with GFAP, vimentin or nestin in glial cells, whereas synemin L was found in neurons.
Bronchial biopsies of asthmatic patients show a negative correlation between desmin expression in airway smooth muscle cell (ASMC) and airway hyperresponsiveness. We previously showed that desmin is an intracellular load-bearing protein, which influences airway compliance, lung recoil, and airway contractile responsiveness (Shardonofsky, F. R., Capetanaki, Y., and Boriek, A. M. (2006) Am. J. Physiol. Lung Cell. Mol. Physiol. 290, L890–L896). These results suggest that desmin may play an important role in ASMC homeostasis. Here, we report that ASMCs of desmin null mice (ASMCsDes−/−) show hypertrophy and up-regulation microRNA-26a (miR-26a). Knockdown of miR-26a in ASMCsDes−/− inhibits hypertrophy, whereas enforced expression of miR-26a in ASMCsDes+/+ induces hypertrophy. We identify that Egr1 (early growth responsive protein-1) activates miR-26a promoter via enhanced phosphorylation of Erk1/2 in ASMCsDes−/−. We show glycogen synthase kinase-3β (GSK-3β) as a target gene of miR-26a. Moreover, induction of ASMCsDes−/− hypertrophy by the Erk-1/2/Egr-1/miR-26a/GSK-3β pathway is consistent in human recombinant ASMCs, which stably suppresses 90% endogenous desmin expression. Overall, our data demonstrate a novel role for desmin as an anti-hypertrophic protein necessary for ASMC homeostasis and identifies desmin as a novel regulator of microRNA.
Transcriptional activity of serum response factor (SRF) is dependent on its binding to the CC(A/T)(6)GG box (CArG box) of serum response element (SRE). By Raman spectroscopy, we carried out a comparative analysis, in solution, of the complexes obtained from the association of core-SRF with 20-mer SREs bearing wild-type and mutated c-fos CArG boxes. In case of association with the wild type c-fos CArG box, the complex does not bring out the expected Raman signature of a stable bending of the targeted SRE but keeps a bend-linear conformer oligonucleotide interconversion. The linear conformer population is larger than that of free oligonucleotide. In the core-SRF moiety of the wild-type complex a large spectral change associated with the CO-groups from Asp and/or Glu residues shows that their ionization states and the strength of their interactions decrease as compared to those of mutated non-specific complexes. Structural constraints evidenced on the free core-SRF are released in the wild-type complex and environmental heterogeneities appear in the vicinity of Tyr residues, due to higher water molecule access. The H-bonding configuration of one Tyr OH-group, in average, changes with a net transfer from H-bond acceptor character to a combined donor and acceptor character. A charge repartition distributed on both core-SRF and targeted SRE stabilizes the specific complex, allowing the two partners to experience a variety of conformations.